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Neoplastic growth is frequently associated with genomic DNA methylation that causes transcriptional silencing of
tumor suppressor genes. We used a collection of colorectal polyps and carcinomas in combination with
bioinformatics analysis of large datasets to study the expression and methylation of Hypermethylated in cancer 1
(HIC1), a tumor suppressor gene inactivated in many neoplasms. In premalignant stages, HIC1 expression was
decreased, and the decrease was linked to methylation of a specific region in the HIC1 locus. However, in
carcinomas, the HIC1 expression was variable and, in some specimens, comparable to healthy tissue. Importantly,
high HIC1 production distinguished a specific type of chemotherapy-responsive tumors.
Translational Oncology (2016) 9, 99–107Introduction
Cancer is viewed as a genetic disease caused by mutations of
protooncogenes and tumor suppressors. It is presumed that the first
oncogenic mutation provides selective advantage to the prospective
cancer cells that multiply and form the initial neoplastic lesion.
Moreover, solid tumors develop over time by acquiring additional
alterations that drive tumor progression (reviewed in [1]). Thesealterations might include extensive changes in methylation of
genomic DNA that (presumably) contribute to tumorigenesis by
transcriptional silencing of tumor suppressor genes (reviewed in [2]).
Adenocarcinomas affecting colon and rectum [colorectal carcino-
ma (CRC)] represent a major cause of morbidity and mortality in
developed countries. Colorectal cancer is the third most common
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numerous CRCs using massive parallel sequencing and DNA
microarray technologies in a comprehensive manner, yielding an
unprecedented insight into the pathobiology of CRC. Consequently,
the commonly accepted division of CRCs into microsatellite instable
neoplasia frequently associated with increased mutation rates and
CpG island methylated phenotype (CIMP), and those that display
microsatellite stability but are chromosomally unstable, was recently
revised (reviewed in [4]). Based on the differences in global expression
profiles, six independent classification systems were proposed,
dividing CRCs into three to six distinct molecular subtypes [5–10].
Very recently, reevaluation of published large-scale data resulted in
subdivision of CRCs into four consensus molecular subtypes (CMSs)
[11]. Importantly, because RNA expression profiles are tightly linked
to the tumor phenotype, CRCmolecular classification not only might
improve the patient staging system but also could identify molecules
or pathways for specific therapeutic interventions.
HIC1 is a tumor suppressor gene located on chromosome 17p13.3, a
chromosomal region that is frequently hypermethylated, rearranged, or
lost in various human cancers, including colon, lung, brain, breast,
prostate, and leukemia (reviewed in [12]). The HIC1 gene encodes an
evolutionarily conserved transcriptional repressor. It is presumed that
HIC1 promoter hypermethylation leads to its silencing; however,
only a limited number of reports have shown the relation between
HIC1 methylation and expression, or the results are conflicting. For
example, HIC1 promoter hypermethylation was detected in healthy
brain and prostate, but because the level of the HIC1 gene expression
was not determined, no conclusion could be drawn from the
observation [13–15]. Additionally, during liver carcinogenesis, the
HIC1 locus was increasingly methylated compared with the healthy
tissue, precancerous lesions, and primary hepatocellular carcinomas.
However, HIC1 expression did not correlate significantly with the
extent of genomic DNA methylation [16,17].
In the present study, we analyzed the HIC1 expression pattern and
locus methylation during neoplastic progression of human colorectal
tumors. We used a collection of polyps and carcinomas, and, in
addition, we employed large publicly available datasets that included
gene expression profiling, high-throughput sequencing, and DNA
methylation data of more than 970 human CRC specimens. We show
that in premalignant stages, HIC1 expression is indeed decreased, and
the decrease is related to the extent of DNA methylation in a specific
region in theHIC1 locus. However, in CRC,HIC1 expression is more
variable, and some specimens display HIC1 mRNA levels comparable
to those observed in healthy tissue. Importantly, highHIC1 production
distinguishes stroma-rich tumors responsive to chemotherapy.
Materials and Methods
Patients and Tissue Samples
Paired samples of normal and neoplastic tissue were obtained from
74 patients undergoing either polypectomy or surgical resection of
sporadic CRC (Supplementary Table S1). The central portion of the
tumor and corresponding normal colonic mucosa from the resection
margin or at least 10 cm from the site of polypectomy were taken,
immediately frozen, and stored in liquid nitrogen. None of the
patients underwent radiotherapy or chemotherapy before the
operation. The study was approved by the Ethics Committee of the
Third Faculty of Medicine, Charles University, in Prague, and all
patients signed the written consent to participate in the study.Total RNA and Genomic DNA Isolation, cDNA Synthesis
Deep-frozen tissue samples were disrupted in 600 μl of lysis buffer
by ceramic beads during one run of MagNA Lyser Instrument (Roche
Life Sciences), and total RNA and genomic DNA were extracted
using AllPrep DNA/RNA Mini kit (Qiagen) according to manufac-
turer’s instructions. The cDNA synthesis was performed in 20-μl
reaction using 1 μg of total RNA, random hexamers, and RevertAid
reverse transcriptase (Thermo Scientific) according to the manufac-
turer’s protocol.
Quantitative Reverse Transcription Polymerase Chain Reaction
(qRT-PCR)
Reactions were run in triplicates using LightCycler 480 Probes
Master and Universal ProbeLibrary hydrolysis probes and Light-
Cycler 480 Instrument (Roche Life Sciences). The primer pairs and
corresponding Universal ProbeLibrary probes are listed in Supple-
mentary Table 2. Crossing point-PCR-cycle (Cp) values for each
triplicate were normalized by geometric average of housekeeping
genes ubiquitin B (UBB) and TATA box binding protein (TBP).
Resulting values were averaged to obtain ΔCp values for biological
replicates. Relative mRNA abundance (ΔCp in healthy tissue − ΔCp
in neoplastic tissue) was correlated with the histological grade of
tumor samples using the rank-order Spearman’s (ρ) and Kendall’s (τ)
coefficient. Neoplastic progression was assumed as follows: hyper-
plasia (Hyp) b low-grade dysplasia (LGD) b high-grade dysplasia
(HGD) b CRC [18].
HIC1 Immunohistochemistry
Five-micrometer sections from formalin-fixed and paraffin-
embedded tissue samples were dewaxed in xylene and rehydrated.
To unmask the antigen sites, the sections were immersed in a steam
bath (20 minutes) in Target Retrieval Solution (Dako). Primary
rabbit anti-HIC1 polyclonal antibody (ab33029, Abcam) was applied
at 1:200 dilution overnight at 4°C. The primary antibody was
detected using EnVision+ System (Dako), and the brown color
reaction was developed with DAB (Vector Laboratories) substrate.
DNA Methylation Analysis of the HIC1 Locus in Patient
Samples
Genomic DNA was isolated from deep-frozen tissue (disintegrated
by MagNa Lyser System; Roche Life Sciences) using AllPrep DNA/
RNA Mini kit (Qiagen). Bisulfite modification of genomic DNA
(0.5 μg) from healthy and neoplastic tissue from HGD (n = 5) and
CRC (n = 6) patients was performed using Imprint DNA Modifi-
cation Kit (Sigma-Aldrich). Bisulfite-treated DNA was amplified
using KAPA 2G Robust Hot Start ReadyMix (KapaBiosystems) and
the following primers: hFHIC1: 5′-ATTATTTTTTTTAATT
GGGGTAATTTTTT-3′ and hRHIC1: 5′-CCAAAACACCTAAC
TAAATACTAAAACTTC-3′. The purified products were subcloned
into the pGEM-T-Easy vector (Promega), and at least eight positive
clones were sequenced. Sequencing data for CpG methylation were
analyzed using the online quantification tool for methylation analysis
(QUMA) (Laboratory for Mammalian Epigenetic Studies, Center for
Developmental Biology, RIKEN).
Public CRC Datasets and Statistical Analysis
The GSE33113 [6] dataset was retrieved from ArrayExpress [19]
(accession E-GEOD-33113); the GSE13294 [20], GSE14333 [21],
and GSE62080 [22] datasets were retrieved from the Gene
igure 1. Analysis ofHIC1 expression in colorectal neoplasia. (A)HIC1
xpression changes during tumor progression. qRT-PCR analysis of
he HIC1mRNA levels in healthy tissue, hyperplastic adenomas (Hyp;
= 9), adenomas displaying low-grade (LGD; n = 24) or high-grade
GD; n = 25) dysplasia, and CRC (n = 12). The boxed areas
orrespond to the second and third quartiles; the median of ΔCp
alues for each category is indicated as the red line. The relation
etween the HIC1 expression profile and neoplasia progression is
ignificant, as evidencedby theSpearman’s (ρ = −0.67) andKendall’s
= −0.51) coefficient values. (B)HIC1 expression in CRC subgroups
lustered according to the DNA methylation profiles. HIC1-high and
IC1-low samples are indicated by brown or blue dots, respectively.
lack dots indicate the other specimens. The red lines correspond to
he median values; log2-expression intensity, binary logarithm of
xpression intensity (additional details are given in Supplementary
ethods).
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(TCGA) data were accessed from the TCGA repository (Broad
Institute, Massachusetts Institute of Technology, USA) on April 13,
2015. The expression, methylation, and mutational analyses are
described in Supplementary material. All computations and statistical
tests were performed in the R environment [24].
Results and Discussion
Region-Specific Methylation of the HIC1 locus in CRC
To determine changes in the HIC1 expression levels during
neoplastic progression, we analyzed total RNA isolated from the
matched healthy colonic mucosa and neoplastic tissue obtained from
74 patients. In adenomas, we observed significant decreases in HIC1
expression in polyps with low- and high-grade dysplasia when
compared with healthy or hyperplastic tissue. HIC1 expression in
CRCs was more heterogeneous, with median positioned between
healthy/hyperplastic and dysplastic samples (Figure 1A). To explore
the relationship between HIC1 expression and the methylation status
of CRCs, we interrogated the relevant dataset recently available from
the TCGA consortium (https://tcga-data.nci.nih.gov/tcga/; 277
specimens in total; the dataset was designated TCGA 450K; see
Supplementary Materials and Methods for details). Unsupervised
clustering of DNA methylation profiles identified four subgroups of
tumors. Two of the subgroups contained CRCs with elevated
methylation and were classified according to previously published
nomenclature [25,26] as CIMP-high and CIMP-low. The two
non-CIMP clusters were designated non–CIMP I and non–CIMP II.
In addition, we employed TCGA gene expression data and
determined (relative) HIC1 mRNA expression levels in each CRC.
Samples that (according toHIC1 expression) fell into the first and last
decile were defined as “HIC1-high” and “HIC1-low,” respectively.
The majority of the HIC1-high samples were distributed among the
CIMP-low, non–CIMP I, and non–CIMP II subgroups. Surprising-
ly, we did not observe clear correlation between the CRC CIMP
status and HIC1 expression. In fact, one HIC1-high sample was
found in the CIMP-high subgroup. Moreover, the HIC1-low samples
were “scattered” among all four subgroups (Figure 1B). To analyze
the methylation rate of HIC1, we evaluated the methylation status of
the HIC1 locus. A substantial portion of mammalian genes contain
the so-called CpG island, a promoter region rich in CpG nucleotides
that are frequently methylated (reviewed in [27]). However, several
studies have shown that most of the methylation changes in cancer
DNA do not occur in the promoter CpG islands but in the regions
located up to 2 kbp apart or even more distant. Importantly, the
methylation status of these CpG island “shores” or “shelves” is
strongly related to gene expression [28–30]. Up to six different HIC1
isoforms were detected in various tissues with predominance of
HIC1a mRNA. These isoforms are produced by differential splicing
or usage of three alternative promoters (reviewed in [31]).
Accordingly, two CpG islands and adjacent shores and shelves
(including all three promoters) were assigned to the locus (Figure 2A).
Using the TCGA 450K dataset, we retrieved information about
methylation of 62 DNA probes covering a large portion of the HIC1
gene. Methylation probes with median of the methylated fraction
equal to or greater than 50% (beta value ≥ 0.5) in the CIMP-high
subgroup and median of the methylated fraction equal to or lesser
than 20% (beta value ≤ 0.2) in both non-CIMP subgroups were
considered as CIMP status-related (Supplementary Figure S1).Additionally, methylation probes whose methylation correlated
with decreasing HIC1 expression (LM-fit coefficient ≤ −1) were
identified as expression-related (Supplementary Figure S2). Interest-
ingly, we identified 31 CIPM-related methylation probes that were
located exclusively in CpG island 1. In contrast, all seven probes
related to HIC1 expression were found in CpG island/shore 2.
Subsequently, we confirmed the observation by testing methylation
of genomic DNA isolated from our collection of healthy and
neoplastic colorectal tissue. The cytosine methylation analysis was
performed in the shore region upstream to CpG island 2 because the
very high CG content of the island itself precluded any unbiased
evaluation (Figure 3A). Analysis of the sequence containing 10 CpGF
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Figure 2. Identification of the CIMP-related and gene expression–relatedHIC1methylation sites. Top, theHIC1 gene exon-intron structure
indicating the position of the major HIC1a transcript driven from the P1 promoter; the position of two alternative promoters P2 and P0 is
also shown. A color-based classification of two CpG islands and other elements is indicated under the schemes; methylation probes
covering the HIC1 locus are indicated as horizontal bars. The bottom panels depict the HIC1methylation status in 277 CRC cases present
in the TCGA 450K dataset. In the left panel, the specimens were grouped according to the CIMP status of tumor DNA; each specimen is
represented by a horizontal bar. The right panel shows the HIC1 methylation status in CRCs classified as HIC1-high or HIC1-low; the
sample with the HIC1 locus deletion is indicated by red arrow. The extent of methylation of CIMP-related (yellow) and expression-related
probes (green) is shown as the gray-shaded heatmap of beta values (unmethylated: white; completely methylated: black); notice the
different “slope” of beta values between the left and right panel. Probes are listed vertically with their identification code in a successive
order according to their target sequence coordinates (the 5′ gene end is shown on the left). The CRC methylation profile of four probes
boxed in pink is shown in Supplementary Figure S1. The correlation between HIC1 expression and the methylation profile of these four
probes is given in Supplementary Figure S2.
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increased methylation in DNA isolated from HGD specimens when
compared with DNA obtained from the matched healthy mucosa
(Figure 3B). Additionally, in CRCs, we observed a clear difference in
the methylation status between the HIC1-high and HIC1-low
specimens (Figure 3C). We noted a complete absence of methylation
in the expression-related region in one sample from the HIC1-low
group (red arrow in Figure 2). However, subsequent copy-numbervariation analysis revealed deletion of the chromosomal region
harboring the HIC1 locus in this particular sample, thus explaining
the lack of the signal. HIC1 transcription is activated by p53 [32,33],
and we therefore analyzed TP53 gene mutations in TCGA 450K
CRCs. However, we did not find any significant differences in the
TP53 status in HIC1-high [3 specimens harboring wild-type (wt)
and 21 specimens mutant TP53] when compared with HIC1-low
samples (5 wt vs 15 mutant specimens). Nevertheless, this does not
Figure 3. Cytosine methylation analysis of the HIC1 locus. (A) Original and bisulfite-modified DNA sequence containing the second
(alternative) HIC1 exon (boxed in grey). Methylation probes included in the region are indicated by red arrows above the sequences. CpG
dinucleotides located in the sequence covered by the probes are in red; other CpG dinucleotides are in green. (B) Methylation of genomic
DNA isolated from colorectal polyps displaying HGD and genomic DNA obtained from matched healthy tissue. Open circles mark
unmethylated CpG dinucleotides, whereas closed circles indicate methylated CpGs; the numbering and color code of CpGs correspond
to their positions in the analyzed genomic DNA as indicated in (A). (C) Cytosine methylation analysis of genomic DNA isolated from three
HIC1-high and three HIC1-low CRCs.
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might—next to the epigenetic modifications—contribute to HIC1
expression.
High HIC1 Expression in CRCs Responsive to Chemotherapy
Next, we asked whether the HIC1 expression level is connected
with some specific pathological CRC features using information
contained in the TCGA 450K and additional three datasets TCGA
27K [34], GSE13294 [20], and GSE14333 [21] (the latter two
datasets were processed together). Rather surprisingly, that is,
considering the tumor suppressive role of HIC1, patients withHIC1-high CRCs displayed lower survival than patients with
HIC1-low CRCs, although a significant difference was reached in
the TCGA 27K dataset only (Figure 4A). Interestingly, an opposite
phenomenon, that is, association of higher HIC1 expression with
better clinical outcome, was observed in breast [35] or lung cancer
[36]. The discrepancy might be attributed to the fact that more
progressed malignancies prevailed among HIC1-high CRCs (Sup-
plementary Figure S3). On the other hand, according to cancer-
treatment related information retrieved from the GSE13294,
GSE14333, and GSE62080 [22] datasets, patients from theHIC1-high
group responded significantly better to FOLFIRI treatment than
Figure 4. HIC1-high CRCs are responsive to FOLFIRI treatment. (A) Kaplan-Meier plots of patient survival for indicated datasets. (B)
Assignment of HIC1-high/low CRCs from the GSE13294 and GSE14333 datasets according to CRC subtype clustering and FOLFIRI
response as described in reference [9]. *P b .05; ***P b .001 (Student’s t test).
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Figure S4). Of note, FOLFIRI, that is, combination of folinic
acid (FOL/leucovorin), 5-fluorouracil, and topoisomerase inhibitor
irinotecan (IRI), is used as the first-line therapy to improve maximal
survival of patients with metastatic CRCs [37]. Based on expression
profiles, we clustered CRCs from these datasets to stem-like,
enterocyte, transit-amplifying, goblet-like, and inflammatory sub-
types [9]. Interestingly, 53% of HIC1-high tumors (n = 21) were
assigned to the stem-like tumors that were associated with clinical
benefits of FOLFIRI treatment (Figure 4B).
The HIC1-High CRC Group and CMS4 Cancer Subtype
Relationship
Finally, we obtained another CRC dataset, GSE33113 [6], and
employed expression data representing 971 CRCs in total to identify
the expression signature that distinguishes HIC1-high from
HIC1-low CRC samples. Unbiased hierarchical clustering revealed
298 genes whose expression differed significantly between HIC1-high
and HIC1-low tumors (Figure 5A, Supplementary Table S3). All
these genes except C2 calcium-dependent domain containing 4A
(C2CD4A) were upregulated in HIC1-high samples. This indicated—
considering the transcriptionally repressive function of HIC1—that
the selected genes are not directly regulated by HIC1. Indeed, none
of the previously identified HIC1-repressed genes [38–48] was
present among the genes. Nevertheless, qRT-PCR analysis of
C2CD4A and five other genes highly upregulated in HIC1-high
samples using eight CRC samples from our experimental collection
(four CRCs were selected as HIC1-high, additional four as
HIC1-low) supported the observation made “in silico” (Figure 5B).
Additionally, the obtained gene set was evaluated using the Enricher
gene library online tool (http://amp.pharm.mssm.edu/Enrichr/)
[49]. We performed gene set enrichment analysis to assign the“Gene Ontology Biological Processes” (GO Biological Processes),
Kyoto Encyclopedia of Genes and Genomes pathways, and “GO
Cellular Components” categories to the signature genes. The
analysis revealed that the majority of identified genes encode
secreted proteins that are involved in extracellular matrix orga-
nization and focal adhesion (Supplementary Figure S5, Supplementary
Table S4).
Subsequently, we stratified individual CRC samples into four
recently defined CMSs [11]. Strikingly, all HIC1-high samples were
present in the CMS4 subtype (Figure 5C) that is characterized by
stromal invasion, activation of transforming growth factor β (TGF-β)
signaling, and extracellular matrix remodeling and complement-me-
diated inflammatory pathways. Indeed, genes encoding the TGF-β1
ligand and complement components were present among upregulated
genes in HIC1-high tumors (Supplementary Table S4). Very
recently, Calon and colleagues described an aggressive stem-like/
mesenchymal CRC subtype with poor prognosis. Strikingly, the
expression profile of this particular CRC subtype is related to the gene
expression program induced by TGF-β in tumor stromal cells [50].
To this end, we compared genes upregulated in HIC1-high tumors
with the TGF-β response gene signatures in different types of stromal
cells. We found significant overlaps of gene profiles by TGF-β–
activated normal colonic fibroblasts (including HIC1 that was among
the TGF-β–activated genes), macrophages, and endothelial cells
(Supplementary Table S5). This would suggest that (in some CRCs)
HIC1 is expressed in stromal rather than in epithelial tumor cells.
However, immunohistochemical staining clearly revealed HIC1-
positive nuclei (and the cytoplasm) in the healthy colonic epithelium
and in tumor cells in HIC1-high CRC samples. Additionally, HIC1
positivity was detected in the nuclei of cells present in the lamina
propria and in tumor stroma of both HIC1-high and HIC1-low
samples (Figure 5D).
Figure 5. All HIC1-high tumors are present in the CMS4 CRC subtype. (A) Venn diagram indicating numbers of genes differentially
expressed in HIC1-high versus HIC1-low CRCs in the indicated datasets; significance criterion: q value b 0.05; absolute value of log2 of
relative expression intensity (|log2 FC|) ≥ 1 for at least one of the gene-specific probes. (B) qRT-PCR analysis of genes differentially
expressed in HIC1-high (n = 4) and HIC1-low (n = 4) CRCs. HIC1-high CRC upregulated genes: elastin microfibril interfacer 1 (EMILIN1),
EGF containing fibulin-like extracellular matrix protein 2 (EFEMP2), latent transforming growth factor beta binding protein 2 (LTBP2),
matrix-remodeling associated 8 (MXRA8); downregulated gene: C2CD4A. (C) Assignment of HIC1-high, HIC1-low, and “other” specimens
from the TCGA 450K dataset to the CMS groups. (D) Representative microscopy images of HIC1 protein immunohistochemical detection
using DAB staining (brownish precipitate). HIC1-positive epithelial and lamina propria cells in the healthy colon are indicated by black and
green arrows, respectively. Red arrows point at HIC1-positive epithelial cancer cells in HIC1-high CRC. Anti-HIC1 staining was also
observed in the stroma (s) of both HIC1-high and HIC1-low CRC tumors. The specimens were counterstained with hematoxylin (blue
nuclei). Magnification: 200×.
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in colorectal tumors [51]. Interestingly, Chen and colleagues reported
that the HIC1 gene was induced in primary lung cancer cells
cocultured with cancer-associated fibroblasts [52]. In addition,
exposure of non–small cell lung cancer cells to TGF-β also led to
the increased HIC1 mRNA levels [53]. Of note, both observations
were obtained upon interrogation of the corresponding datasets
deposited by the authors to the ArrayExpress repository at https://
www.ebi.ac.uk/arrayexpress. Finally, Briones and colleagues found
that the repression of fibroblast growth factor-binding protein 1 by
TGF-β signaling depends on HIC1 [40]. These data suggest a
functional relationship between cancer and stromal (i.e., TGF-β-
producing) cells in HIC1-expressing CRCs. In contrast, Calon and
colleagues reported that because of the mutations in genes encoding
components of TGF-β signaling, many epithelial cancer cells are not
responsive to the TGF-β cues [50]. To solve this possible discrepancy,
we used exome sequence data from the TCGA 450K dataset toidentify mutations in the TGFβ1 branch of TGF-β signaling in the
CMS4 group of tumors. We found frequent missense mutations in
the SMAD4 gene encoding the common cytoplasmic/nuclear
mediator of the signaling. However, these mutations were equally
distributed among HIC1-high and “other” tumors. Nonetheless,
none of the identified inactivating mutations [affecting genes
encoding TGFBR1, SMAD2, and SMAD4] was found in HIC1-high
samples. Interestingly, in 17 of 50 CRCs, we did not detect any
mutations in the TGFβ1-dependent branch of the pathway
(Supplementary Figure S6). This might imply that epithelial cancer
cells in (some) stroma-rich CRCs retained TGF-β responsiveness.
How is HIC1 (re)expression in CRC regulated? What is the function
of the protein in progressed CRC, and why is a portion of the HIC1
protein in tumor cells cytoplasmic? These intriguing questions remain
to be elucidated. However, our results clearly indicate that HIC1
expression defines a group of CRCs sensitive to FOLFIRI treatment.
The study also documents how high-throughput approaches started
106 HIC1 Expression in Intestinal Cancer Janeckova et al. Translational Oncology Vol. 9, No. 2, 2016to shape current biomedical and molecular biology research.
Clinically relevant data can be produced by “data mining” of large
publicly available datasets that are complemented by experiments
using a relatively small collection of clinical samples.
Conclusions
(1) Region-specific methylation dictates the HIC1 expression
levels in intestinal cancer.
(2) High HIC1 production distinguishes stroma-rich carcinomas
responsive to chemotherapy.
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